Find Psilly | Article

As the promise of psychedelic therapies for mental health conditions gains momentum, an intense race to secure patents on various aspects of psilocybin therapy is underway. Companies like Compass Pathways, a leading psychedelic medicine firm, are actively filing patent claims to gain exclusive rights, but this approach has sparked concerns among scientists and patient advocates about potential barriers to access and stifling academic research.

The Patent Rush in Psychedelic Medicine

Patent applications for psilocybin therapy have covered a wide range of elements, from therapy room décor to drug delivery methods. Compass Pathways, with a valuation of $450 million, has been especially aggressive in filing more than 50 patent claims over the past few years. Other competitors have also joined in, collectively submitting over a hundred patent applications to the U.S. Patent and Trademark Office, some of which have been granted while others rejected.

The Need for Investment and Protection

Compass Pathways' co-founder and executive chairman, George Goldsmith, defends the company's patent strategy, citing the necessity of raising hundreds of millions of dollars for conducting clinical trials at numerous sites across Europe and North America. This investment is critical for gaining regulatory approval and encouraging private and government insurers to cover psychedelic therapies. Goldsmith emphasizes that this extensive undertaking cannot be accomplished through philanthropy alone.

Challenges and Criticisms

The push for patents in the psychedelic industry has drawn criticism from scientists and advocates who fear that such tactics might hinder academic research and make these therapies unaffordable for many. While the FDA has shown interest in exploring new therapeutic uses for psychedelics, the surge in patent filings has complicated the landscape.

Robin Feldman, an expert on pharmaceutical intellectual property, points out that the conflict over psychedelics reflects larger problems in a patent system that contributes to high drug prices in the United States. Some worry that corporatization could divert talented scientists from academic research and reduce philanthropic support.

Balancing Profit and Access

Critics emphasize that psychedelic therapies should be accessible and affordable to patients, and the focus should not solely be on maximizing profits through patent monopolies. Some companies are developing modified versions of existing compounds to lower costs, but there are concerns about the implications of shorter psychedelic experiences without adequate psychotherapy.

Navigating the Path Forward

The race for psychedelic therapy patents is emblematic of the growing interest and investment in this emerging field. While investors and researchers are excited about the transformative potential of psychedelic medicine, finding a balance between commercial interests and public access is a pressing challenge.

Efforts to Challenge Patent Claims

In response to excessive patent claims, a group called Porta Sophia has emerged to provide patent officials with prior art evidence, which can help reject flawed or overly broad patent applications. This effort aims to protect the integrity of psychedelic research and prevent monopolies that could deter newcomers from entering the field.